Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5% - Here's Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares fell 5.5% during trading on Tuesday . The company traded as low as $21.61 and last traded at $21.77. 36,787 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 280,797 shares. The stock had previously closed at $23.04.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on DNTH. Raymond James upgraded Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th. Oppenheimer upped their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an "outperform" rating in a report on Monday, November 11th. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Finally, TD Cowen assumed coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They issued a "buy" rating for the company. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $46.43.

Dianthus Therapeutics Stock Down 13.7 %

The firm has a market cap of $588.39 million, a price-to-earnings ratio of -7.95 and a beta of 1.74. The firm has a fifty day moving average price of $24.38 and a 200-day moving average price of $26.60.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $2.17 million during the quarter, compared to analysts' expectations of $1.07 million. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in Dianthus Therapeutics during the 3rd quarter valued at approximately $556,000. Barclays PLC boosted its position in Dianthus Therapeutics by 390.5% during the 3rd quarter. Barclays PLC now owns 41,684 shares of the company's stock worth $1,141,000 after acquiring an additional 33,185 shares during the period. Bank of New York Mellon Corp grew its position in Dianthus Therapeutics by 860.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company's stock valued at $2,095,000 after buying an additional 72,509 shares in the last quarter. HighVista Strategies LLC acquired a new stake in shares of Dianthus Therapeutics in the 3rd quarter worth approximately $542,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Dianthus Therapeutics by 142.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company's stock valued at $4,543,000 after acquiring an additional 97,362 shares in the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.